Allergan Stock Buy Or Sell Apr 2026

As of April 2026, . The company was acquired by AbbVie (NYSE: ABBV) in a $63 billion deal that officially closed on May 8, 2020.

: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms allergan stock buy or sell

: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq . As of April 2026,

Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue. now branded as Allergan Aesthetics

If you previously held Allergan (AGN) shares, they were converted during the 2020 merger according to the following terms: AbbVie Completes Transformative Acquisition of Allergan

: The Allergan division, now branded as Allergan Aesthetics , continues to lead the global medical aesthetics market with products like Botox.